Basel, Switzerland, 1 September 2025 - NBE Therapeutics is pleased to announce that Olof Prause will take on the role of Chief Operating Officer (COO) starting September 1, 2025. Olof brings extensive experience in operational leadership, project management, and strategic development, making him a valuable addition to the company’s management team.

In his new role, Olof will lead NBE-Therapeutics’ operational strategy and execution, ensuring the company’s mission to advance its Antibody-Drug Conjugate (ADC) portfolio and deliver transformative cancer therapies.

Prior to joining NBE-Therapeutics, Olof held various leadership roles at Boehringer Ingelheim, where he contributed to development projects across different lifecycle stages, managed global manufacturing and launch operations, and drove strategic initiatives. He also played a pivotal role in assessing external opportunities and successfully integrating acquired companies, showcasing his ability to lead cross-functional teams and deliver impactful results.

NBE Therapeutics is thrilled to welcome Olof Prause to the team and looks forward to his contributions as the company continues to push the boundaries of innovation in cancer treatment.